Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eisai

FDA grants full approval to new Alzheimer’s drug - Roll Call

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Roll Call

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com

An Alzheimer's drug is on the way, but getting it may still be tough. Here's why

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Axios

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use

U.S. health advisers are backing the full approval of an Alzheimer's drug that received preliminary approval last year

The Independent UK

UK on verge of new dawn for dementia treatments, says taskforce chair

Today’s generation of older people could be last to face untreatable Alzheimer’s – but only if NHS overhauls care

The Guardian - UK

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Why a new Alzheimer's drug is having a slow US debut

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away

The Independent UK

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

StockNews.com

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune

What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

The Conversation

3 Biotech Stocks to Help Boost Your Portfolio in January

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

StockNews.com

Finally, a new drug slows Alzheimer’s, but is it worth the price for modest benefit?

Leqembi can slow early progression by months but has safety concerns. Most patients will likely have to wait months to get the IV drug, which will cost about $26,500 a year. Insurers need to decide whether and how much to cover it. Medicare isn’t expected to pay for it until…

Chicago Sun-Times

EXPLAINER: New drug slows Alzheimer's but comes with caveats

A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Asharq Al-Awsat

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

The Independent UK

Alzheimer’s drug that slows disease progression approved by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

Axios

FDA grants fast-track approval to experimental Alzheimer's drug

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

The Independent UK

Alzheimer's drug that modestly slows disease OK'd by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

Get all your
news in one place.

100's of premium titles.
One news app.

Manchester Evening News

Eleven good things that happened in the world in 2022

It's been a tough year in so many ways - so let's take a look back at some of the more positive moments

Bangkok Post

Japan approves simple Alzheimer’s blood test

TOKYO: Japan’s health ministry has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the brain-wasting ailment for which a blockbuster therapy is finally on the horizon.

The Conversation

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

WEKU

Is lecanemab the Alzheimer's drug that will finally make a difference?

The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.

Tribune News Service

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Al Jazeera

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Manchester Evening News

Drug proven to slow decline in Alzheimer patients

Lecanemab, a newly developed drug, has showed promising results in clinical trials among Alzheimer patients

1 2 3 4

People

Nazanin Zaghari-Ratcliffe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

347 stories

LLY

337 stories

the Food and Drug Administration

Alzheimer Research UK

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.